Lineage Cell Therapeutics, Inc. - FORM 10-K - EX-21.1 - EXHIBIT 21.1 - March 15, 2016

Attached files

file	filename
EX-23.2 - EXHIBIT 23.2 - Lineage Cell Therapeutics, Inc.	ex23_2.htm
EX-31 - EXHIBIT 31 - Lineage Cell Therapeutics, Inc.	ex31.htm
EX-23.1 - EXHIBIT 23.1 - Lineage Cell Therapeutics, Inc.	ex23_1.htm
EX-10.68 - EXHIBIT 10.68 - Lineage Cell Therapeutics, Inc.	ex10_68.htm
EX-10.69 - EXHIBIT 10.69 - Lineage Cell Therapeutics, Inc.	ex10_69.htm
EX-32 - EXHIBIT 32 - Lineage Cell Therapeutics, Inc.	ex32.htm
10-K - BIOTIME, INC 10-K 12-31-2015 - Lineage Cell Therapeutics, Inc.	form10k.htm

Exhibit 21.1

List of Subsidiaries

Subsidiary	BioTime Ownership	Country
Ascendance Biotechnology, Inc.	46.1%⁽¹⁾	USA
Asterias Biotherapeutics, Inc. (NYSE MKT: AST)	5.1%	USA
BioTime Asia, Limited	81%	Hong Kong
Cell Cure Neurosciences Ltd.	62.5%⁽²⁾	Israel
ES Cell International Pte Ltd	100%	Singapore
LifeMap Sciences, Inc.	77.9%	USA
LifeMap Sciences, Ltd.	(3)	Israel
LifeMap Solutions, Inc.	(3)	USA
OncoCyte Corporation (NYSE MKT: OCX)	57.7%	USA
OrthoCyte Corporation	100%	USA
ReCyte Therapeutics, Inc.	94.8%	USA

(1)

Includes shares owned by BioTime, ESI and ReCyte.

(2)

Includes shares owned by BioTime and ESI.

(3)

LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.